PMCC PMCC

Search tips
Search criteria

Advanced
Results 1-3 (3)
 

Clipboard (0)
None
Journals
Authors
Year of Publication
Document Types
1.  A comparative study on efficacy of Bharangyadi Avaleha and Vasa Avaleha in the management of Tamaka Shwasa with reference to childhood asthma 
Ayu  2011;32(1):82-89.
Ayurvedic concept is of the opinion that Tamaka Shwasa (Bronchial Asthma) is a Yapya Vyadhi. The etiopathogenesis, signs, and symptoms of Tamaka Shwasa may be correlated with Bronchial Asthma. Each child reacts differently to the factors that trigger asthma and treated symptomatically. Asthma is the most common chronic allergic disorder in childhood and third leading cause of hospitalization under the age of 15 years. As it is a Kapha-Vata predominant disorder, Ayurvedic medicine may help to decrease the recurrence, improve immunity, and check symptoms naturally. With this aim, a clinical study was undertaken on two groups for duration of 6 weeks. The drugs Bharangyadi Avaleha and Vasa Avaleha were given orally, separately in both the groups. All the patients were kept under strict dietary control during the treatment. The observation on effect of therapy was encouraging and showed less recurrence.
doi:10.4103/0974-8520.85736
PMCID: PMC3215424  PMID: 22131763
Bharangyadi Avaleha; childhood asthma; Tamaka Shwasa; Vasa Avaleha
2.  Effect of Triphaladi Avaleha as an adjuvant therapy in the management of Thalassemia 
Ayu  2010;31(4):403-409.
Thalassemia is the most common inherited single-gene (autosomal recessive) disorder in the world. Scientists worldwide predict that thalassemia will become a considerable health issue in the next century. It is a new disease entity for Ayurvedic medicine, and hence, it is called Anukta Vyadhi in Ayurveda; but we can understand it by careful scrutiny of the clinical presentation and the investigation results described in the available literature. Modern medical management is aimed at maintaining the hemoglobin level at 10 – 12 g/dl. A post-transfusion hemoglobin level of 9.5 g/dl is said to be sufficient to maintain active life. Thus, blood transfusion therapy is the only treatment, but it can result in hemosiderosis (iron overload), a complication with a fatal outcome. The transfusional iron overload is compounded by increased intestinal absorption of iron. The most important factors associated with survival, and also those deciding the outcome of bone marrow transplant (the only curative therapy) are, age at which chelation therapy is introduced and the success with which serum ferritin is maintained below 2500 ng/ml. Iron chelators used in modern medicine to achieve this goal are expensive and associated with side effects, and hence, associated with poor adherence to the treatment. The present study is an endeavor to explore the efficacy of Triphaladi Avaleha as an iron chelator in the management of thalassemia, in comparison to a control group managed by routine modern therapy.
doi:10.4103/0974-8520.82026
PMCID: PMC3202272  PMID: 22048530
Thalassemia; Anukta Vyadhi; Hemosiderosis; Triphaladi Avaleha; Serum Ferritin
3.  Evaluation of Dhatri Avaleha as adjuvant therapy in Thalassemia (Anukta Vyadhi in Ayurveda) 
Ayu  2010;31(1):19-23.
Thalassemia is the commonest single gene disorder in India. About 10,000 infants with Thalassemia major are born every year. The present study was under taken with a hope to prevail better quality of life to the Thalassemic patients. Pallor being the chief complaint, a randomized controlled trial was undertaken with Dhatri Avaleha as it is specially mentioned for Pandu, Kamala & Haleemaka Roga. Children between age group of 1 to 15 years were randomly divided in two groups: Drug treated group (Group A) and Control group (Group B). Assessment was done on subjective and objective parameters after 30 and 60 days of treatment with follow up of two month. Statistically significant (P<0.01) result was obtained in Blood transfusion interval in group ‘A’ in comparison to group ‘B’. Dhatri Avaleha may have a potential to increase blood transfusion interval and decrease secondary infection and thus it can be used as supportive therapy with modern medical management.
doi:10.4103/0974-8520.68199
PMCID: PMC3215316  PMID: 22131679
Thalassemia; Pandu; Kamala; Haleemaka; Dhatri Avaleha

Results 1-3 (3)